W06-038: Evaluation of a new drug for treatment of chronic renal failure in cats–Control of renal secondary hyperparathyroidism in cats with chronic renal failure: a new approach using calcimimetic drugs

Chronic kidney failure is a common problem affecting millions of cats each year. Current management strategies are inadequate and many cats still exhibit significant signs of illness and have an overall reduced quality of life. The buildup of multiple toxins in the bloodstream plays a significant role in kidney failure. Parathyroid hormone (PTH) is one such toxin identified in people with kidney failure. PTH is produced in small glands in the neck called parathyroid glands. PTH is critical in the control of calcium and phosphorus in the body. In cats the role of PTH as a significant toxin has not been substantially explored. Studies in human beings have shown that PTH can be responsible for long-term consequences of kidney disease, including mineralization of various tissues, decreased ability to fight off infection, and anemia. Recently a new class of drugs was developed for human medicine to treat elevated levels of PTH. These drugs are called calcimimetic drugs, and they cause decreased PTH production. We believe the use of calcimimetic drugs may prolong survival and increase quality of life for cats with chronic kidney failure, similar to results in human beings.

Grant ID: W06-038

Status: Active

Year Funded: 2006

Amount awarded: $13,345

Investigator: Thomas K. Graves, DVM, PhD, DACVIM; Melissa R. Riensche, DVM. University of Illinois, Urbana, IL